RENAGADE THERAPEUTICS
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

RENAGADE THERAPEUTICS Trademark

Serial Number: 97620656

RENAGADE THERAPEUTICS is a trademark filed by ReNAgade Therapeutics Management Inc. on October 5, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

ReNAgade Therapeutics Management Inc. (7 trademarks)

500 Forge Rd.
Watertown, MA 02472

Entity Type: 03

Trademark Details

Filing Date

October 5, 2022

Registration Date

Not Registered

Published for Opposition

December 19, 2023

Goods & Services

Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy containing polypeptide encoding nucleic acids for the prevention and/or treatment of rare diseases, cancers, diabetes, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for in vitro, in vivo, or ex vivo delivery to a cell, organ, tissue, or body; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of infectious diseases, blood disorders, diabetes, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, for the prevention of osteoporosis; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics for the treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral infections; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for treating diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for use in chemotherapy; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, namely, antivirals; Vaccine preparations; Vaccines; Anti-epileptic pharmaceutical preparations; veterinarian vaccine preparations; Medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral and joint diseases

Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, and chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, and for use in the manufacture of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Reagents for testing sterility of pharmaceuticals; Diagnostic reagents for scientific or research use; chemicals for use in biotherapeutics, biosimilars and therapeutics product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use; Biochemical catalysts; Biochemical preparations for scientific purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations used in science; Nucleic acid for laboratory use; Protein in raw material form for scientific and medical research; Reagents for research purposes; Reagents for scientific and research use; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Antioxidants for use in the manufacture of pharmaceuticals; Biochemicals for in vitro, in vivo, and ex vivo scientific use; Biochemicals, namely, polypeptides for in vitro research use; Biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research purposes; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Catalysts for chemical and biochemical processes; Cells for scientific, laboratory or medical research; Chemical additives for use in the manufacture of pharmaceuticals; Chemicals for use in the biochemical and chemical industry; Chemicals for use in the purification of proteins for in vitro use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Enzymes for use in protein hydrolysis; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Plant extracts for use in the manufacture of pharmaceuticals; Protein arrays and nucleotide arrays for scientific and medical research; Reagents for scientific or medical research use

Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design, engineering, genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy and cell therapy, research, development and testing services in the field of pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics in the nature of linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; Medical and scientific research in the field of cancer treatment and diagnosis; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of nucleic acids, inhibitory nucleic acids, protein-encoding nucleic acids and polypeptide-encoding nucleic acids; Pharmaceutical research and development; Product research and development; Scientific research and development; Vaccine research and development

Filing History

SOU TEAS EXTENSION RECEIVED
Mar 31, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 3, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 2, 2026 EX4G
SOU EXTENSION 4 FILED
Feb 2, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 2, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2025 EXRA
SOU EXTENSION 3 GRANTED
Aug 11, 2025 EX3G
SOU EXTENSION 3 FILED
Aug 11, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 11, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 13, 2025 EXRA
SOU EXTENSION 2 GRANTED
Feb 13, 2025 EX2G
SOU EXTENSION 2 FILED
Feb 12, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 12, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 4, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 4, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 4, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 4, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 4, 2024 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 31, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jul 31, 2024 EX1G
SOU EXTENSION 1 FILED
Jul 31, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 31, 2024 EEXT
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 20, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 20, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 20, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 20, 2024 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 13, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 14, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 6, 2023 TROA
ASSIGNED TO EXAMINER
Oct 4, 2023 DOCK
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 7, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 19, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 22, 2022 NWOS
NEW APPLICATION ENTERED
Oct 8, 2022 NWAP